Cendakimab selectively targets interleukin (IL)-13, a type 2 cytokine implicated in atopic dermatitis (AD) pathogenesis, by inhibiting binding to its receptors (IL13R-α1 and IL13R-α2). Proof-of-concept work in AD supports using cendakimab for type 2 inflammatory diseases.
PDF的下载单位、IP信息已删除
(2025-6-4)
冰魂
爱静静
tramp
平常的毛豆
风清扬
FIN
机灵柚子
iNk
Cactus
科研助手6
scm
eric888
HEIKU
MchemG
pcr163
谨慎的夏蓉
热心市民小红花
xiaxiao
孙燕
shinysparrow
皖公网安备34019202002308
